Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8765430rdf:typepubmed:Citationlld:pubmed
pubmed-article:8765430lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:8765430lifeskim:mentionsumls-concept:C0005961lld:lifeskim
pubmed-article:8765430lifeskim:mentionsumls-concept:C0018183lld:lifeskim
pubmed-article:8765430lifeskim:mentionsumls-concept:C1518999lld:lifeskim
pubmed-article:8765430lifeskim:mentionsumls-concept:C0300926lld:lifeskim
pubmed-article:8765430lifeskim:mentionsumls-concept:C0040739lld:lifeskim
pubmed-article:8765430lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:8765430pubmed:dateCreated1996-9-17lld:pubmed
pubmed-article:8765430pubmed:abstractTextPeripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplantation, sufficient PBSC or PBPC must be infused. To confirm the utility of granulocyte colony-stimulating factor (G-CSF) in chemotherapy-induced PBSC mobilization, we investigated the effect of G-CSF on PBSC mobilization in leukemia and lymphoma patients. The study design was such that PBSC mobilization with and without G-CSF was assessed in the same patients. The results indicate that PBSC mobilization can be enhanced significantly when G-CSF is given during the recovery phase postchemotherapy. Interestingly, progenitor cells of different lineages could be mobilized by G-CSF. We subsequently investigated the effect of increasing G-CSF dose on PBSC mobilization during steady-state hematopoiesis in healthy adult donors. The results indicate that not only committed but also primitive progenitor cells are mobilized into the circulation in a dose-and time-dependent manner when G-CSF at 5, 10, or 15 micrograms/kg was given on each of 5 days and leukapheresis was performed on day 6. From our data we estimate that sufficient PBSC for engraftment after allogeneic PBSC transplantation can be collected on day 5 of administration of G-CSF at 10 micrograms/kg and by 10-1 leukapheresis on days 5 and 6. Furthermore, we found that some G-CSF-mobilized PBSC retained their self-renewal capability. These observations suggest that hematopoietic stem cells for allogeneic PBSC transplantation can be mobilized by short-term administration of relatively high-dose G-CSF.lld:pubmed
pubmed-article:8765430pubmed:languageenglld:pubmed
pubmed-article:8765430pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8765430pubmed:citationSubsetIMlld:pubmed
pubmed-article:8765430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8765430pubmed:statusMEDLINElld:pubmed
pubmed-article:8765430pubmed:issn0344-5704lld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:KubotaAAlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:OhnoYYlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:TakenakaKKlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:MizunoSSlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:HaradaMMlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:LaraF YFYlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:EtoTTlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:AkashiKKlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:MiyamotoTTlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:TeshimaTTlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:OkamuraTTlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:InabaSSlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:KuroiwaMMlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:TakamatsuYYlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:GondoHHlld:pubmed
pubmed-article:8765430pubmed:authorpubmed-author:FujisakiTTlld:pubmed
pubmed-article:8765430pubmed:issnTypePrintlld:pubmed
pubmed-article:8765430pubmed:volume38 Suppllld:pubmed
pubmed-article:8765430pubmed:ownerNLMlld:pubmed
pubmed-article:8765430pubmed:authorsCompleteYlld:pubmed
pubmed-article:8765430pubmed:paginationS115-9lld:pubmed
pubmed-article:8765430pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8765430pubmed:meshHeadingpubmed-meshheading:8765430-...lld:pubmed
pubmed-article:8765430pubmed:meshHeadingpubmed-meshheading:8765430-...lld:pubmed
pubmed-article:8765430pubmed:meshHeadingpubmed-meshheading:8765430-...lld:pubmed
pubmed-article:8765430pubmed:meshHeadingpubmed-meshheading:8765430-...lld:pubmed
pubmed-article:8765430pubmed:meshHeadingpubmed-meshheading:8765430-...lld:pubmed
pubmed-article:8765430pubmed:meshHeadingpubmed-meshheading:8765430-...lld:pubmed
pubmed-article:8765430pubmed:year1996lld:pubmed
pubmed-article:8765430pubmed:articleTitleGranulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation. Fukuoka Bone Marrow Transplantation Group.lld:pubmed
pubmed-article:8765430pubmed:affiliationSecond Department of Internal Medicine, Okayama University Medical School, Japan.lld:pubmed
pubmed-article:8765430pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8765430pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed